Progress in the Research and Development of Biphenyl Small Molecules Targeting PD‐1/PD‐L1 as Potential Antitumor Drug Candidates
ChemMedChem · 02.08.2025 · 20 (15)
DOI: 10.1002/cmdc.202500179 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 12.05.2025. Verfasst von Wei He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lab of Chemical Biology and Molecular Drug DesignCollege of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China. Hauptthemen laut MEDLINE: Biphenyl Compounds, Programmed Cell Death 1 Receptor, Antineoplastic Agents, B7-H1 Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 94 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Key Discipline of Chemical Biology.
Abstract (Originalsprache)
Cancer remains a major global health challenge, and cancer immunotherapy has emerged as a promising treatment strategy. A key immune checkpoint in this approach is the interaction between PD‐1 and PD‐L1, which suppresses immune responses against tumor cells. Although monoclonal antibodies targeting PD‐1/PD‐L1 have shown significant therapeutic potential, their use is hampered by limitations such as high costs, extended half‐lives, and the potential for immune‐related side effects. In response to these challenges, there is growing interest in the development of small‐molecule inhibitors that can disrupt the PD‐1/PD‐L1 interaction more efficiently and cost‐effectively. This review focuses on the design of biphenyl‐based small molecules as inhibitors of the PD‐1/PD‐L1 pathway. We explore various design strategies, key structural features, and recent advancements in biphenyl‐derived compounds. These insights contribute to the ongoing effort to develop alternative antitumor therapies with improved pharmacological profiles and therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lab of Chemical Biology and Molecular Drug DesignCollege of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China.
- Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, 313299, China.
- Research and Development Department, Zhejiang Qingzhenghong Technology Co., Ltd, Hangzhou, 311121, China.
- Department of Physical Chemical and Toxicology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310051, China.
- Research and Development Department, Zhejiang Jieyuan Med-Tech Co., Ltd., Hangzhou, 311113, China.
ORCID-Profile: Yanhua Song, Jianwei Wang, Wen Zhang
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Key Discipline of Chemical Biology
Zitieren
APA
He, W., Xu, H., Awadasseid, A., Song, Y., Wang, J., & Zhang, W. (2025). Progress in the Research and Development of Biphenyl Small Molecules Targeting PD‐1/PD‐L1 as Potential Antitumor Drug Candidates. ChemMedChem, 20(15). https://doi.org/10.1002/cmdc.202500179
Vancouver
He W, Xu H, Awadasseid A, Song Y, Wang J, Zhang W. Progress in the Research and Development of Biphenyl Small Molecules Targeting PD‐1/PD‐L1 as Potential Antitumor Drug Candidates. ChemMedChem. 2025;20(15). doi:10.1002/cmdc.202500179
BibTeX
@article{He2025,
author = {He, Wei and Xu, Haoran and Awadasseid, Annoor and Song, Yanhua and Wang, Jianwei and Zhang, Wen},
title = {Progress in the Research and Development of Biphenyl Small Molecules Targeting PD‐1/PD‐L1 as Potential Antitumor Drug Candidates},
journal = {ChemMedChem},
year = {2025},
volume = {20},
number = {15},
doi = {10.1002/cmdc.202500179}
}
EUVIMED